File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Management of advanced hepatocellular carcinoma in the era of targeted therapy

TitleManagement of advanced hepatocellular carcinoma in the era of targeted therapy
Authors
KeywordsAdvanced hepatocellular carcinoma
Bevacizumab
Sorafenib
Targeted therapy
Issue Date2009
PublisherWiley-Blackwell Publishing, Inc.. The Journal's web site is located at http://www.wiley.com/bw/journal.asp?ref=1478-3223&site=1
Citation
Liver International, 2009, v. 29 n. 1, p. 10-17 How to Cite?
AbstractSystemic chemotherapy has had a disappointing track record in the management of advanced hepatocellular carcinoma (HCC). Single-agent doxorubicin produces a response rate of 10-15%, but without any survival benefit, and combination chemotherapy has also yielded unimpressive results. With recent advances in the knowledge of hepato-carcinogenesis, there has been encouraging development in the systemic therapy of advanced HCC patients, and particularly in the targeted therapy of advanced HCC. Among the newly identified targets, exciting results have been shown in targeting the anti-angiogenic pathway and the Raf/ mitogen-activated protein kinase pathways. Bevacizumab, both as a single agent and in combination with other agents, has shown initial encouraging activity in treating advanced HCC. More recently, single-agent sorafenib, a putative multitargeted kinase inhibitor, has shown to prolong the overall survival of patients with advanced HCC in the pivotal phase III Sorafenib HCC Assessment Randomized Protocol (SHARP) and Oriental study. Currently, sorafenib is the only approved targeted therapy for patients with advanced HCC. In addition, however, promising early results have been reported for other molecular-targeted drugs including erlotinib and sunitinib. Future progress seems likely to depend on using controlled clinical trials to optimize synergistic combination treatments. © 2009 The Authors. Journal compilation © 2009 Blackwell Munksgaard.
Persistent Identifierhttp://hdl.handle.net/10722/132650
ISSN
2015 Impact Factor: 4.47
2015 SCImago Journal Rankings: 1.677
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorYau, Ten_HK
dc.contributor.authorChan, Pen_HK
dc.contributor.authorEpstein, Ren_HK
dc.contributor.authorPoon, RTPen_HK
dc.date.accessioned2011-03-28T09:27:24Z-
dc.date.available2011-03-28T09:27:24Z-
dc.date.issued2009en_HK
dc.identifier.citationLiver International, 2009, v. 29 n. 1, p. 10-17en_HK
dc.identifier.issn1478-3223en_HK
dc.identifier.urihttp://hdl.handle.net/10722/132650-
dc.description.abstractSystemic chemotherapy has had a disappointing track record in the management of advanced hepatocellular carcinoma (HCC). Single-agent doxorubicin produces a response rate of 10-15%, but without any survival benefit, and combination chemotherapy has also yielded unimpressive results. With recent advances in the knowledge of hepato-carcinogenesis, there has been encouraging development in the systemic therapy of advanced HCC patients, and particularly in the targeted therapy of advanced HCC. Among the newly identified targets, exciting results have been shown in targeting the anti-angiogenic pathway and the Raf/ mitogen-activated protein kinase pathways. Bevacizumab, both as a single agent and in combination with other agents, has shown initial encouraging activity in treating advanced HCC. More recently, single-agent sorafenib, a putative multitargeted kinase inhibitor, has shown to prolong the overall survival of patients with advanced HCC in the pivotal phase III Sorafenib HCC Assessment Randomized Protocol (SHARP) and Oriental study. Currently, sorafenib is the only approved targeted therapy for patients with advanced HCC. In addition, however, promising early results have been reported for other molecular-targeted drugs including erlotinib and sunitinib. Future progress seems likely to depend on using controlled clinical trials to optimize synergistic combination treatments. © 2009 The Authors. Journal compilation © 2009 Blackwell Munksgaard.en_HK
dc.languageengen_US
dc.publisherWiley-Blackwell Publishing, Inc.. The Journal's web site is located at http://www.wiley.com/bw/journal.asp?ref=1478-3223&site=1en_HK
dc.relation.ispartofLiver Internationalen_HK
dc.subjectAdvanced hepatocellular carcinomaen_HK
dc.subjectBevacizumaben_HK
dc.subjectSorafeniben_HK
dc.subjectTargeted therapyen_HK
dc.titleManagement of advanced hepatocellular carcinoma in the era of targeted therapyen_HK
dc.typeArticleen_HK
dc.identifier.emailYau, T: tyaucc@hku.hken_HK
dc.identifier.emailEpstein, R: repstein@hku.hken_HK
dc.identifier.emailPoon, RTP: poontp@hku.hken_HK
dc.identifier.authorityYau, T=rp01466en_HK
dc.identifier.authorityEpstein, R=rp00501en_HK
dc.identifier.authorityPoon, RTP=rp00446en_HK
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1111/j.1478-3231.2008.01916.xen_HK
dc.identifier.pmid19120940-
dc.identifier.scopuseid_2-s2.0-57749203825en_HK
dc.identifier.hkuros167037-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-57749203825&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume29en_HK
dc.identifier.issue1en_HK
dc.identifier.spage10en_HK
dc.identifier.epage17en_HK
dc.identifier.eissn1478-3231-
dc.identifier.isiWOS:000261685700005-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridYau, T=23391533100en_HK
dc.identifier.scopusauthoridChan, P=7403497715en_HK
dc.identifier.scopusauthoridEpstein, R=34975074500en_HK
dc.identifier.scopusauthoridPoon, RTP=7103097223en_HK
dc.identifier.citeulike3809924-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats